Art of Industry Partnership honors a for-profit biotechnology, pharmaceutical, or genetics company whose track record models the benefits of creative partnerships between consumer advocates and industry to advance understanding and treatment of genetic conditions, disorders, and diseases.

Talecris Biotherapeutics, Inc., is a global biotherapeutics company that discovers, develops, and manufactures critical-care treatments in a variety of theraputic areas for people with life-threatening disorders. The Talecris mission is to provide innovative biotherapeutics that enhance life and create value for patients, employees, communities, and investors around the world. Talecris is proudly building on a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization, as well as strategic initiatives that leverage its strengths with those of its partners.

Talecris has a long history of commitment to patient communities, sponsoring a variety of programs and services both globally and locally that advance care, support education and disease awareness, and supplement internal Talecris research and development efforts to increase scientific knowledge related to rare diseases. A 17-year partnership with the Alpha-1 community is a hallmark of the Talecris commitment to advocacy organizations.

For more information, visit the company’s website, www.talecris.com.